228 related articles for article (PubMed ID: 34230198)
1. Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials.
Wolters PL; Vranceanu AM; Thompson HL; Martin S; Merker VL; Baldwin A; Barnett C; Koetsier KS; Hingtgen CM; Funes CJ; Tonsgard JH; Schorry EK; Allen T; Smith T; Franklin B; Reeve S;
Neurology; 2021 Aug; 97(7 Suppl 1):S50-S63. PubMed ID: 34230198
[TBL] [Abstract][Full Text] [Related]
2. Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis.
Merker VL; Bredella MA; Cai W; Kassarjian A; Harris GJ; Muzikansky A; Nguyen R; Mautner VF; Plotkin SR
Am J Med Genet A; 2014 Jun; 164A(6):1431-7. PubMed ID: 24664633
[TBL] [Abstract][Full Text] [Related]
3. Patient Report of Hearing in Neurofibromatosis Type 2: Recommendations for Clinical Trials.
Thompson HL; Blanton A; Franklin B; Merker VL; Franck KH; Welling DB;
Neurology; 2021 Aug; 97(7 Suppl 1):S64-S72. PubMed ID: 34230203
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials.
Wolters PL; Martin S; Merker VL; Gardner KL; Hingtgen CM; Tonsgard JH; Schorry EK; Baldwin A;
Neurology; 2013 Nov; 81(21 Suppl 1):S6-14. PubMed ID: 24249806
[TBL] [Abstract][Full Text] [Related]
5. Perspectives of adults with neurofibromatosis regarding the design of psychosocial trials: Results from an anonymous online survey.
Wolters PL; Ghriwati NA; Baker M; Martin S; Berg D; Erickson G; Franklin B; Merker VL; Oberlander B; Reeve S; Rohl C; Rosser T; Vranceanu AM
Clin Trials; 2024 Feb; 21(1):73-84. PubMed ID: 37962219
[TBL] [Abstract][Full Text] [Related]
6. Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.
Thompson HL; Grabowski J; Franklin B; Koetsier KS; Welling DB
Clin Trials; 2024 Feb; 21(1):18-28. PubMed ID: 38321701
[TBL] [Abstract][Full Text] [Related]
7. Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.
Merker VL; Thompson HL; Wolters PL; Buono FD; Hingtgen CM; Rosser T; Barton B; Barnett C; Smith T; Haberkamp D; McManus ML; Baldwin A; Moss IP; Röhl C; Martin S
Clin Trials; 2024 Feb; 21(1):6-17. PubMed ID: 38140900
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials.
Wolters PL; Martin S; Merker VL; Tonsgard JH; Solomon SE; Baldwin A; Bergner AL; Walsh K; Thompson HL; Gardner KL; Hingtgen CM; Schorry E; Dudley WN; Franklin B;
Neurology; 2016 Aug; 87(7 Suppl 1):S4-S12. PubMed ID: 27527648
[TBL] [Abstract][Full Text] [Related]
9. Minimal clinically important difference in the World Health Organization Quality of Life Brief (WHOQOL-BREF) for adults with neurofibromatosis.
Pietrzykowski MO; Vranceanu AM; Macklin EA; Mace RA
Qual Life Res; 2024 May; 33(5):1233-1240. PubMed ID: 38214851
[TBL] [Abstract][Full Text] [Related]
10. First use of patient reported outcomes measurement information system (PROMIS) measures in adults with neurofibromatosis.
Talaei-Khoei M; Riklin E; Merker VL; Sheridan MR; Jordan JT; Plotkin SR; Vranceanu AM
J Neurooncol; 2017 Jan; 131(2):413-419. PubMed ID: 27900643
[TBL] [Abstract][Full Text] [Related]
11. Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis.
Ahlawat S; Fayad LM; Khan MS; Bredella MA; Harris GJ; Evans DG; Farschtschi S; Jacobs MA; Chhabra A; Salamon JM; Wenzel R; Mautner VF; Dombi E; Cai W; Plotkin SR; Blakeley JO; ;
Neurology; 2016 Aug; 87(7 Suppl 1):S31-9. PubMed ID: 27527647
[TBL] [Abstract][Full Text] [Related]
12. Recommendations for Social Skills End Points for Clinical Trials in Neurofibromatosis Type 1.
Janusz JA; Klein-Tasman BP; Payne JM; Wolters PL; Thompson HL; Martin S; de Blank P; Ullrich N; Del Castillo A; Hussey M; Hardy KK; Haebich K; Rosser T; Toledo-Tamula MA; Walsh KS;
Neurology; 2021 Aug; 97(7 Suppl 1):S73-S80. PubMed ID: 34230205
[TBL] [Abstract][Full Text] [Related]
13. Clinical features of spinal schwannomas in 65 patients with schwannomatosis compared with 831 with solitary schwannomas and 102 with neurofibromatosis Type 2: a retrospective study at a single institution.
Li P; Zhao F; Zhang J; Wang Z; Wang X; Wang B; Yang Z; Yang J; Gao Z; Liu P
J Neurosurg Spine; 2016 Jan; 24(1):145-54. PubMed ID: 26407091
[TBL] [Abstract][Full Text] [Related]
14. Baseline characteristics of adults with neurofibromatosis enrolled on a psychosocial randomized controlled trial.
Fishbein NS; Vranceanu AM; Mace RA
J Neurooncol; 2022 Sep; 159(3):637-646. PubMed ID: 35925531
[TBL] [Abstract][Full Text] [Related]
15. The PedsQL as a patient-reported outcome in children and adolescents with fibromyalgia: an analysis of OMERACT domains.
Varni JW; Burwinkle TM; Limbers CA; Szer IS
Health Qual Life Outcomes; 2007 Feb; 5():9. PubMed ID: 17295915
[TBL] [Abstract][Full Text] [Related]
16. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature.
Vranceanu AM; Merker VL; Park E; Plotkin SR
J Neurooncol; 2013 Sep; 114(3):257-62. PubMed ID: 23817811
[TBL] [Abstract][Full Text] [Related]
17. Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis.
Merker VL; Dai A; Radtke HB; Knight P; Jordan JT; Plotkin SR
BMC Health Serv Res; 2018 Aug; 18(1):668. PubMed ID: 30157837
[TBL] [Abstract][Full Text] [Related]
18. PedsQL Neurofibromatosis Type 1 Module for children, adolescents and young adults: feasibility, reliability, and validity.
Nutakki K; Varni JW; Swigonski NL
J Neurooncol; 2018 Apr; 137(2):337-347. PubMed ID: 29273891
[TBL] [Abstract][Full Text] [Related]
19. Achieving consensus for clinical trials: the REiNS International Collaboration.
Plotkin SR; Blakeley JO; Dombi E; Fisher MJ; Hanemann CO; Walsh KS; Wolters PL; Widemann BC
Neurology; 2013 Nov; 81(21 Suppl 1):S1-5. PubMed ID: 24249801
[TBL] [Abstract][Full Text] [Related]
20. Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.
Vranceanu AM; Manglani HR; Choukas NR; Kanaya MR; Lester E; Zale EL; Plotkin SR; Jordan J; Macklin E; Bakhshaie J
JAMA Netw Open; 2023 Jun; 6(6):e2320599. PubMed ID: 37378983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
